2-{5-[tert-butyl(methyl)carbamoyl]-2-methylphenyl}-6-(4-fluorophenyl)-N-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide | 1438844-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{5-[tert-butyl(methyl)carbamoyl]-2-methylphenyl}-6-(4-fluorophenyl)-N-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide
• 英文别名: 2-[5-[tert-butyl(methyl)carbamoyl]-2-methylphenyl]-6-(4-fluorophenyl)-N-methylimidazo[2,1-b][1,3]thiazole-5-carboxamide
• CAS: 1438844-30-4
• 化学式: C₂₆H₂₇FN₄O₂S
• 分子量: 478.59
• InChiKey: DHXHNOINXDJCSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  95
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] BENZOTHIAZINE COMPOUNDS AS H3 RECEPTOR LIGANDS<br/>[FR] COMPOSÉS BENZOTHIAZINES EN TANT QUE LIGANDS DE RÉCEPTEUR H3
  申请人：OXYGEN HEALTHCARE RES PVT LTD

  公开号：WO2013076590A1

  公开（公告）日：2013-05-30

  The present invention provides benzothiazine derivative of formula (I), useful in the treatment of CNS disorders including cognitive disorders, ADHD, narcolepsy, pain, dementias, schizophrenia as well as obesity and sleep disorders. Pharmacological profile of these compounds includes high affinity binding with H3 receptor along with favourable selectivity profile for other aminergic receptors. The present invention also includes 'their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions.

  本发明提供了式(I)的苯并噻嗪衍生物，用于治疗包括认知障碍、注意力缺陷多动障碍、嗜睡症、疼痛、痴呆症、精神分裂症以及肥胖症和睡眠障碍在内的中枢神经系统疾病。这些化合物的药理特性包括与H3受体的高亲和结合，以及对其他胺能受体有良好的选择性特征。本发明还包括它们的类似物、它们的互变异构体、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、它们的药学上可接受的溶剂合物和药学上可接受的组合物。
• [EN] COMPOUNDS FOR THE TREATMENT OF HCV<br/>[FR] COMPOSÉS DESTINÉS À TRAITER LE VHC
  申请人：BIOTA SCIENT MANAGEMENT

  公开号：WO2013075173A1

  公开（公告）日：2013-05-30

  The present invention relates to viral polymerase inhibitors of formula (I) or salts, solvates, hydrates, racemates, enantomers or isomers thereof, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

  本发明涉及公式(I)或其盐、溶剂化物、水合物、外消旋体、对映体或同分异构体的病毒聚合酶抑制剂，特别是Flaviviridae家族内的病毒聚合酶抑制剂，例如丙型肝炎病毒(HCV)，其制备过程以及在治疗Flaviviridae病毒感染，如丙型肝炎病毒(HCV)感染中的应用。